HRP20190162T1 - Lactobacillus reuteri atcc pta 6475 za uporabu za sprječavanje ili liječenje gubitka kosti kod sisavaca - Google Patents

Lactobacillus reuteri atcc pta 6475 za uporabu za sprječavanje ili liječenje gubitka kosti kod sisavaca

Info

Publication number
HRP20190162T1
HRP20190162T1 HRP20190162TT HRP20190162T HRP20190162T1 HR P20190162 T1 HRP20190162 T1 HR P20190162T1 HR P20190162T T HRP20190162T T HR P20190162TT HR P20190162 T HRP20190162 T HR P20190162T HR P20190162 T1 HRP20190162 T1 HR P20190162T1
Authority
HR
Croatia
Prior art keywords
reuters
lactobacillus
mammal
prevention
treatment
Prior art date
Application number
HRP20190162TT
Other languages
English (en)
Croatian (hr)
Inventor
Eamonn Connolly
Robert Allen Britton
Laura Rae MCCABE
Original Assignee
Biogaia Ab
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab, Michigan State University filed Critical Biogaia Ab
Publication of HRP20190162T1 publication Critical patent/HRP20190162T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20190162TT 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 za uporabu za sprječavanje ili liječenje gubitka kosti kod sisavaca HRP20190162T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04
PCT/SE2013/050646 WO2013184064A1 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals
EP13800449.4A EP2854826B9 (en) 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 for use in prevention or treatment of bone loss in mammals

Publications (1)

Publication Number Publication Date
HRP20190162T1 true HRP20190162T1 (hr) 2019-04-05

Family

ID=49712339

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190162TT HRP20190162T1 (hr) 2012-06-04 2013-06-04 Lactobacillus reuteri atcc pta 6475 za uporabu za sprječavanje ili liječenje gubitka kosti kod sisavaca

Country Status (16)

Country Link
US (4) US20150150917A1 (enExample)
EP (2) EP2854826B9 (enExample)
JP (1) JP6193981B2 (enExample)
KR (2) KR102191537B1 (enExample)
CN (1) CN104755091B (enExample)
AU (2) AU2013272330B2 (enExample)
CA (1) CA2875841C (enExample)
DK (2) DK3456334T3 (enExample)
ES (2) ES2847424T3 (enExample)
HR (1) HRP20190162T1 (enExample)
HU (1) HUE042643T2 (enExample)
LT (1) LT2854826T (enExample)
PL (2) PL2854826T3 (enExample)
SI (1) SI2854826T1 (enExample)
TR (1) TR201901771T4 (enExample)
WO (1) WO2013184064A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
US12427174B2 (en) * 2019-02-05 2025-09-30 Biomedit, Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
JP7596301B2 (ja) * 2019-12-02 2024-12-09 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用
KR102937770B1 (ko) * 2023-08-09 2026-03-12 국립한국교통대학교산학협력단 골다공증 억제 균주 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511502A2 (en) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotic therapies using lactobacillus reuteri
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP1918373B1 (en) * 2005-07-26 2014-08-20 Nestec S.A. Anti-obesity agent and anti-obesity food
WO2008028300A1 (en) * 2006-09-07 2008-03-13 Mcgill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Also Published As

Publication number Publication date
KR20150028968A (ko) 2015-03-17
EP2854826A1 (en) 2015-04-08
HUE042643T2 (hu) 2019-07-29
KR20200044134A (ko) 2020-04-28
US20180200313A1 (en) 2018-07-19
US9968643B2 (en) 2018-05-15
EP2854826B9 (en) 2019-05-08
CN104755091A (zh) 2015-07-01
ES2711427T3 (es) 2019-05-03
EP2854826B1 (en) 2018-11-14
AU2013272330B2 (en) 2017-11-02
PL2854826T3 (pl) 2019-06-28
EP2854826A4 (en) 2016-07-06
AU2013272330A1 (en) 2015-01-15
DK2854826T3 (en) 2019-03-11
AU2018200524B2 (en) 2019-07-18
SI2854826T1 (sl) 2019-03-29
US20150150917A1 (en) 2015-06-04
CA2875841C (en) 2021-02-02
JP2015526389A (ja) 2015-09-10
PL3456334T3 (pl) 2021-05-04
HK1211847A1 (en) 2016-06-03
JP6193981B2 (ja) 2017-09-06
EP3456334A1 (en) 2019-03-20
CA2875841A1 (en) 2013-12-12
AU2018200524A1 (en) 2018-02-15
US10232001B2 (en) 2019-03-19
CN104755091B (zh) 2020-07-21
US10537598B2 (en) 2020-01-21
LT2854826T (lt) 2019-02-11
ES2711427T8 (es) 2019-06-20
DK3456334T3 (da) 2021-01-25
TR201901771T4 (tr) 2019-03-21
WO2013184064A1 (en) 2013-12-12
KR102191537B1 (ko) 2020-12-16
ES2847424T3 (es) 2021-08-03
US20170128501A1 (en) 2017-05-11
US20190142879A1 (en) 2019-05-16
EP3456334B1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
HRP20251412T1 (hr) Sredstvo za uporabu u liječenju ili prevenciji oftalmoloških stanja
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
IL236054A0 (en) Compositions and methods for treating Crohn's disease and related conditions and infections
EP2981274A4 (en) Probiotic strains for use in treatment or prevention of osteoporosis
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
ZA201403948B (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
HUE037474T2 (hu) Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
HUE054185T2 (hu) Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
PT3025585T (pt) Composição de controlo de doença de plantas e sua utilização
PT2854910T (pt) Níveis de ceramida no tratamento e prevenção de infeções
SG11201504542PA (en) Probiotic strains for the treatment and/or prevention of diarrhœa
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
EP2991733A4 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
PL2895180T3 (pl) Kompozycja do zapobiegania i leczenia ostrych i nawracających zakażeń dróg moczowych
IL243879B (en) Bivalent vaccines and their use for the treatment of tumors
GB201208850D0 (en) Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
IL243192B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
GB201502240D0 (en) Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels
PT2699545T (pt) Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico